Find Denifanstat manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Tvb-2640, 1399177-37-7, Denifanstat [inn], Denifanstat [usan], Fasn-in-2, 4gf95b2lza
Molecular Formula
C27H29N5O
Molecular Weight
439.6  g/mol
InChI Key
BBGOSBDSLYHMRA-UHFFFAOYSA-N
FDA UNII
4GF95B2LZA

Denifanstat
Denifanstat is an orally bioavailable fatty acid synthase (FASN) inhibitor, with potential antineoplastic activity. Upon administration, denifanstat binds to and blocks FASN, which prevents the synthesis of palmitate needed for tumor cell growth and survival. This leads to a reduction in cell signaling, an induction of tumor cell apoptosis and the inhibition of cell proliferation in susceptible tumor cells. FASN, an enzyme responsible for the de novo synthesis of palmitic acid, is overexpressed in tumor cells and plays a key role in tumor metabolism, lipid signaling, tumor cell survival and drug resistance; tumor cells are dependent on increased fatty acid production for their enhanced metabolic needs and rapid growth.
1 2D Structure

Denifanstat

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1H-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile
2.1.2 InChI
InChI=1S/C27H29N5O/c1-17-14-24(22-4-3-5-22)25(26-29-18(2)30-31-26)15-23(17)27(33)32-12-10-21(11-13-32)20-8-6-19(16-28)7-9-20/h6-9,14-15,21-22H,3-5,10-13H2,1-2H3,(H,29,30,31)
2.1.3 InChI Key
BBGOSBDSLYHMRA-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=CC(=C(C=C1C(=O)N2CCC(CC2)C3=CC=C(C=C3)C#N)C4=NNC(=N4)C)C5CCC5
2.2 Other Identifiers
2.2.1 UNII
4GF95B2LZA
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-1h-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile

2. Tvb-2640

2.3.2 Depositor-Supplied Synonyms

1. Tvb-2640

2. 1399177-37-7

3. Denifanstat [inn]

4. Denifanstat [usan]

5. Fasn-in-2

6. 4gf95b2lza

7. Tvb 2640 [who-dd]

8. 4-(1-(4-cyclobutyl-2-methyl-5-(3-methyl-1h-1,2,4-triazol-5-yl)benzoyl)piperidin-4-yl)benzonitrile

9. 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-4h-1,2,4-triazol-3- Yl)benzoyl)piperidin-4-yl)benzonitrile

10. 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-4h-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile

11. Us8871790, 480

12. 4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1h-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile

13. 4-{1-[4-cyclobutyl-2-methyl-5-(5-methyl-1h-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl}benzonitrile

14. Benzonitrile, 4-(1-(4-cyclobutyl-2-methyl-5-(3-methyl-1h-1,2,4-triazol-5-yl)benzoyl)-4-piperidinyl)-

15. Benzonitrile, 4-[1-[4-cyclobutyl-2-methyl-5-(3-methyl-1h-1,2,4-triazol-5-yl)benzoyl]-4-piperidinyl]-

16. Unii-4gf95b2lza

17. Asc-40

18. Chembl3661754

19. Schembl12488853

20. Bdbm137084

21. Bcp30428

22. Ex-a3643

23. S9714

24. Who 11784

25. Zinc150188638

26. Ac-35714

27. Hy-112829

28. Cs-0066310

29. Tvb2640; Tvb 2640;fasn-in-2

30. A937502

31. Us8871790, 152

2.4 Create Date
2012-10-30
3 Chemical and Physical Properties
Molecular Weight 439.6 g/mol
Molecular Formula C27H29N5O
XLogP35.3
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count4
Rotatable Bond Count4
Exact Mass439.23721057 g/mol
Monoisotopic Mass439.23721057 g/mol
Topological Polar Surface Area85.7 Ų
Heavy Atom Count33
Formal Charge0
Complexity728
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty